The earnings call was largely positive, with significant growth in sales and revenue, successful product launches, and strong cash flow. Despite some challenges such as a catheter recall and increased operating expenses, the company's robust performance and positive outlook overshadowed the lowlights.

Company Guidance -

Q3 2025

During the LeMaitre Vascular Q2 2025 earnings call, the company reported strong financial performance across various metrics, resulting in an increase in full-year guidance for sales, gross margin, operating income, and EPS. Sales increased by 15%, with a 70% gross margin and a 16% rise in EPS. Specifically, sales of catheters were up 27%, grafts increased by 19%, and Valvulotomes were up by 13%. Geographically, EMEA saw a 23% growth, while both the Americas and APAC regions grew by 12%. The international launch of Artegraft surpassed expectations with Q2 sales reaching $420,000, contributing to the forecast of over $2 million in Artegraft sales for FY2025. The company employed 164 sales reps and 33 managers by the end of Q2, with a focus on expanding their direct-to-hospital sales efforts internationally. Additionally, LeMaitre raised its full-year revenue guidance to $251 million with a 15% organic growth expectation and increased its fully diluted EPS guidance by 19% to $2.30.

Strong Sales Growth

Q2 sales increased by 15%, with a gross margin of 70% and EPS up 16%. Catheters grew by 27%, and grafts by 19%. EMEA sales grew 23%, Americas by 12%, and APAC by 12%.

Successful Artegraft Launch

International Artegraft sales reached $420,000 in Q2, up from $185,000 in Q1. Full-year sales are expected to surpass $2 million.

Increased Revenue Guidance

The full-year revenue guidance was raised to $251 million with 15% organic growth. Gross margin expectations are set at 69.7%.

Strong Cash Flow

Cash from operations was a record $20.3 million in Q2, with $319.5 million in cash and securities, an increase of $17 million.

Positive Unit Volume Growth

Unit volume growth was 7% in Q2, driven by Artegraft, XenoSure, RestoreFlow, and catheters.

Increased Sales Representative Workforce

The company ended Q2 with 164 sales reps, supporting direct-to-hospital sales in new markets like Portugal and Czech Republic.

Lemaitre Vascular (LMAT) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

LMAT Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 30, 2025	2025 (Q3)	0.57 / -	0.49	―	―	―
Aug 05, 2025	2025 (Q2)	0.57 / 0.60	0.52	15.38% (+0.08)	―
May 01, 2025	2025 (Q1)	0.50 / 0.48	0.44	9.09% (+0.04)	―
Feb 27, 2025	2024 (Q4)	0.49 / 0.49	0.38	28.95% (+0.11)
Oct 31, 2024	2024 (Q3)	0.43 / 0.49	0.33	48.48% (+0.16)
Aug 01, 2024	2024 (Q2)	0.47 / 0.52	0.36	44.44% (+0.16)
May 02, 2024	2024 (Q1)	0.39 / 0.44	0.27	62.96% (+0.17)
Feb 27, 2024	2023 (Q4)	0.36 / 0.38	0.25	52.00% (+0.13)
Nov 01, 2023	2023 (Q3)	0.31 / 0.33	0.25	32.00% (+0.08)	―
Aug 01, 2023	2023 (Q2)	0.32 / 0.36	0.16	125.00% (+0.20)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

LMAT Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 05, 2025	$85.60	$93.23	+8.91%
May 01, 2025	$90.02	$78.51	-12.79%
Feb 27, 2025	$99.42	$91.40	-8.07%
Oct 31, 2024	$87.82	$94.27	+7.34%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Lemaitre Vascular (LMAT) report earnings?

Lemaitre Vascular (LMAT) is schdueled to report earning on Oct 30, 2025, After Close (Confirmed).

What is Lemaitre Vascular (LMAT) earnings time?

Lemaitre Vascular (LMAT) earnings time is at Oct 30, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is LMAT EPS forecast?

LMAT EPS forecast for the fiscal quarter 2025 (Q3) is 0.57.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing